Seven months after suspending sales of its weight loss balloon in France due to safety concerns, Allurion’s products are back on sale in the country. In August 2024, the US company agreed to ...

Allurion Technologies (ALUR) announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 900,000 shares of the ...

NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today ...

NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a ...

Company considering sites in France for clinical trial on combination therapy of Allurion Balloon and GLP-1s to prevent muscle loss NATICK, Mass., February 13, 2025--(BUSINESS WIRE)--Allurion ...

NATICK, Mass., February 18, 2025--(BUSINESS WIRE)--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity ...

Shares of Allurion Technologies were trading higher in the after-hours market following news the company would initiate a clinical study on the combination of certain weight-loss drugs and its ...

Allurion Technologies Inc. is cleared by regulators in France to resume sales of its swallowable gastric balloon to treat obesity, in the country. Last summer, the company withdrew the Allurion ...

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced ...

Company considering sites in France for clinical trial on combination therapy of Allurion Balloon and GLP-1s to prevent muscle loss Allurion Technologies, Inc. (“Allurion” or the “Company ...

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced ...